ReShape Lifesciences Inc.
RSLS
$2.46
-$0.14-5.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.11M | 1.81M | 2.29M | 1.97M | 1.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.11M | 1.81M | 2.29M | 1.97M | 1.94M |
| Cost of Revenue | 432.00K | 486.00K | 853.00K | 831.00K | 779.00K |
| Gross Profit | 681.00K | 1.32M | 1.44M | 1.13M | 1.17M |
| SG&A Expenses | 2.16M | 1.44M | 2.80M | 2.79M | 2.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.95M | 2.45M | 4.05M | 4.02M | 4.15M |
| Operating Income | -1.84M | -642.00K | -1.76M | -2.05M | -2.21M |
| Income Before Tax | 1.48M | -1.76M | -1.58M | -1.58M | -2.18M |
| Income Tax Expenses | 7.00K | 5.00K | 6.00K | 15.00K | 14.00K |
| Earnings from Continuing Operations | 1.47M | -1.76M | -1.58M | -1.60M | -2.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.47M | -1.76M | -1.58M | -1.60M | -2.19M |
| EBIT | -1.84M | -642.00K | -1.76M | -2.05M | -2.21M |
| EBITDA | -1.84M | -637.00K | -1.76M | -2.05M | -2.20M |
| EPS Basic | 18.98 | -61.71 | -77.68 | -91.69 | -135.37 |
| Normalized Basic EPS | 11.72 | -37.67 | -48.36 | -72.18 | -84.07 |
| EPS Diluted | 18.98 | -61.71 | -77.68 | -91.69 | -135.37 |
| Normalized Diluted EPS | 11.72 | -37.67 | -48.36 | -72.18 | -84.07 |
| Average Basic Shares Outstanding | 77.70K | 28.50K | 20.40K | 17.40K | 16.20K |
| Average Diluted Shares Outstanding | 77.70K | 28.50K | 20.40K | 17.40K | 16.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |